Paclitaxel drug-eluting devices are the gold standard for SFA interventions.
First presented at LINC 2025, TRUE-PTX data show that PAD treatment with paclitaxel drug-eluting devices may reduce the risk of amputation and readmission vs. treatment with non-drug devices. Reducing the risk of amputation with drug-eluting devices potentially leads to a meaningful positive impact on patients' quality of life and avoids significant healthcare costs.
Presented at Charing Cross 2025, authors conducted a sub-analysis of the TRUE-PTX data and compared patients treated with Eluvia DES (N=881) vs. patients treated with a non-DE device (N=5,156). The same positive results were found: PAD treatment with Eluvia DES may reduce the risk of amputation and readmission vs. treatment with non-drug devices.
Truveta aggregates normalized EHR data from more than 120 million de-identified patient records across more than 30 U.S. health systems, enabling the generation of clinical insights that are large-scale, near-real-time, and representative of a broad population of patients and clinicians.
Paclitaxel drug-eluting devices are the gold standard for SFA interventions, proven through comprehensive evidence generated by both RCTs (i.e. EMINENT and RANGER II SFA) and real-world evidence, now including the TRUE-PTX analysis of more than 10,000 patients.
TRUE-PTX Eluvia Subgroup Analysis1
Before matching
12-month amputations occurred less frequently for patients treated with Eluvia DES
| Eluvia | non-DE | P-value | |
|---|---|---|---|
| Any Limb Amputation | 7.7% | 8.9% | 0.265 |
| Same Limb Amputation | 1.9% | 2.3% | 0.391 |
| Any Readmission | 51.9% | 57.8% | 0.001 |
After Matching2
Patients treated with non-DE devices were more likely to have any above-ankle amputation and any readmission compared with Eluvia DES
Treatment with a non-DE device increased odds for any above-ankle amputation by
47%
Treatment with a non-DE device increased odds for any readmission by
23%
Watch the 2025 Charing Cross Symposium Recording
References:
1. Brian DeRubertis. Polymer-based Drug-Eluting Stent vs Bare Device Therapies for PAD In the Real World: 12-Month Amputation and Readmission Rates in a Large Nationwide Population. Presented at CX 23 April 2025.
2. Exact Matching Method.